FORM 4

(First)

NY

(State)

51 ASTOR PLACE, 10TH FLOOR

1. Name and Address of Reporting Person*

NEW YORK

(City)

(Middle)

10003

(Zip)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

vvasnington, D.O. 20

ct	STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: 3235-0287

to Sec	this box if no lot tion 16. Form 4 tions may conti tion 1(b).	or Form 5	STA		pursu	ant t	to Sectio	n 16(a	a) of the	Secu	rities Exchang	je Act o		RSHIP	Est		ber: average bi		0.5
						2. Issuer Name and Ticker or Trading Symbol Verrica Pharmaceuticals Inc. [VRCA]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner					
(Last) (First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 12/21/2023								Officer (give title Other (specify below) below)					,	
51 ASTOR PLACE, 10TH FLOOR				4. If	Line)									or Joint/Group Filing (Check Applicable					
(Street) NEW YORK NY 10003				Form filed by One Reporting Person X Form filed by More than One Reporting Person															
(City) (State) (Zip)				Ru	Rule 10b5-1(c) Transaction Indication														
					<u> </u>	satis	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.										,		
1. Title of	Security (Ins		I - N	2. Transactio	_	2A.	Deemed		3.		sposed of 4. Securities	Acquire	ed (A) or	5. Amou	nt of		nership	7. Nature	
Date (Month/Day/\)				Year) if a		ecution Date, any onth/Day/Year)		Transaction Code (Instr 8)		Disposed Of 5)	(D) (Instr. 3, 4 and		Benefici Owned I Reporte	ally Following d	Form: Dire (D) or Indi (I) (Instr. 4		Indirect Beneficia Ownersh (Instr. 4)	al hip	
					\dashv	\bot				v	Amount	(A) or (D)	Price	Transac (Instr. 3				See	\dashv
Common Stock 12/21/20.				23	23			P		200,000	A	\$6.17	(1) 6,472,914		1		Footno	te ⁽⁴⁾	
Common Stock 12/22/202				23	:3			P		250,000	A	\$6.67	6,72	2,914	1		See Footno	ote ⁽⁴⁾	
Common Stock 12/26/2023								P		54,652	A	\$6.49	6,77	7,566	7,566 I		See Footno	ote ⁽⁴⁾	
		Tal	ole II								posed of, convertib				d				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Exec if any	Deemed ution Date, / th/Day/Year)	4. Transactior Code (Instr. 8)				Expiration I (Month/Day			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitic Benefici Owned Followin Reporte Transac (Instr. 4)	ve es ially ng d tion(s)	10. Ownersl Form: Direct (I or Indire (I) (Instr.	hip of Ind Bene O) Owne ect (Instr	Nature ndirect eficial nership tr. 4)
					Code	v	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amount or Number of Shares						
		Reporting Person*	<u>LC</u>																
(Last) 51 ASTO		(First) , 10TH FLOOR	1)	Middle)															
(Street)	ORK	NY	1	0003															
(City)		(State)	(2	Zip)															
	EPTIVE I	Reporting Person*	CES	MASTEI	<u> </u>														

EDELMAN J	<u>OSEPH</u>						
(Last) (First) (Middle) 51 ASTOR PLACE, 10TH FLOOR							
(Street) NEW YORK	NY	10003					
(City)	(State)	(Zip)					

Explanation of Responses:

- 1. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$6.00 to \$6.52 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range.
- 2. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$6.26 to \$6.89 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range.
- 3. The reported price is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$6.395 to \$6.50 inclusive. The reporting persons undertake to provide the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number shares purchased at each separate price within such range.
- 4. The securities are directly held by Perceptive Life Sciences Master Fund Ltd. (the "Master Fund"). Perceptive Advisors LLC (the "Advisor") serves as the investment manager of the Master Fund. Joseph Edelman is the managing member of the Advisor. Each of Mr. Edelman and the Advisor disclaims, for purposes of Section 16 of the Securities Exchange Act of 1934, beneficial ownership of such securities, except to the extent of his/its indirect pecuniary interest therein, and this report shall not be deemed an admission that either Mr. Edelman or the Advisor is the beneficial owner of such securities for purposes of Section 16 or for any other purposes.

Remarks:

/s/ Perceptive Life Sciences Master Fund Ltd., By: Perceptive Advisors LLC, its 12/26/2023 investment manager By: Joseph Edelman, its managing member /s/ Perceptive Advisors LLC, 12/26/2023 By: Joseph Edelman, its

managing member

12/26/2023 /s/ Joseph Edelman

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.